Among 20 analysts covering Delek US Holdings (NYSE:DK), 11 have Buy rating, 0 Sell and 9 Hold. Therefore 55% are positive. Delek US Holdings had 75 analyst reports since July 24, 2015 according to SRatingsIntel. The firm has “Neutral” rating by JP Morgan given on Tuesday, March 13. The company was maintained on Wednesday, December 20 by RBC Capital Markets. Goldman Sachs upgraded Delek US Holdings, Inc. (NYSE:DK) on Tuesday, May 16 to “Buy” rating. Deutsche Bank maintained the stock with “Hold” rating in Tuesday, January 26 report. The rating was maintained by Howard Weil on Tuesday, August 30 with “Sector Perform”. Cowen & Co maintained it with “Buy” rating and $33.0 target in Thursday, November 9 report. The stock of Delek US Holdings, Inc. (NYSE:DK) earned “Buy” rating by RBC Capital Markets on Thursday, August 3. Wells Fargo upgraded the shares of DK in report on Wednesday, October 7 to “Outperform” rating. Citigroup upgraded the stock to “Buy” rating in Wednesday, February 14 report. As per Friday, March 24, the company rating was downgraded by Credit Suisse. See Delek US Holdings, Inc. (NYSE:DK) latest ratings:
16/04/2018 Broker: Morgan Stanley Old Rating: Overweight New Rating: Overweight Old Target: $44 New Target: $53 Maintain
13/04/2018 Broker: RBC Capital Markets Rating: Buy New Target: $49.0000 Maintain
10/04/2018 Broker: Credit Suisse Rating: Outperform New Target: $47 Initiates Coverage On
09/04/2018 Broker: Scotia Capital Rating: Buy New Target: $46.0000 Maintain
09/04/2018 Broker: JP Morgan Old Rating: Neutral New Rating: Neutral Old Target: $43 New Target: $44 Maintain
19/03/2018 Broker: Deutsche Bank Old Rating: Hold New Rating: Hold Old Target: $43 New Target: $46 Maintain
13/03/2018 Broker: JP Morgan Old Rating: Neutral New Rating: Neutral Old Target: $41 New Target: $43 Maintain
27/02/2018 Broker: Cowen & Co Rating: Buy New Target: $40.0 Maintain
28/02/2018 Broker: Citigroup Old Rating: Buy New Rating: Buy Old Target: $43 New Target: $46 Maintain
15/02/2018 Broker: Bank of America Rating: Hold New Target: $37.0 Downgrade
The stock of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) is a huge mover today! The stock decreased 3.54% or $3.96 during the last trading session, reaching $107.78. About 5.04 million shares traded or 132.24% up from the average. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has declined 8.84% since April 22, 2017 and is downtrending. It has underperformed by 20.39% the S&P500.The move comes after 8 months negative chart setup for the $23.97B company. It was reported on Apr, 22 by Barchart.com. We have $99.16 PT which if reached, will make NASDAQ:ALXN worth $1.92 billion less.
The stock increased 1.02% or $0.47 during the last trading session, reaching $46.76. About 984,135 shares traded. Delek US Holdings, Inc. (NYSE:DK) has risen 65.09% since April 22, 2017 and is uptrending. It has outperformed by 53.54% the S&P500.
Delek US Holdings, Inc. operates as an integrated energy firm that provides petroleum refining and transportation services. The company has market cap of $3.93 billion. The firm operates in two divisions, Refining and Logistics. It has a 11.7 P/E ratio. The Refining segment owns and operates two refineries in Tyler, Texas, and El Dorado, Arkansas; and produces various petroleum products used in transportation and industrial markets.
Analysts await Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) to report earnings on April, 26 before the open. They expect $1.28 earnings per share, up 6.67% or $0.08 from last year’s $1.2 per share. ALXN’s profit will be $284.62M for 21.05 P/E if the $1.28 EPS becomes a reality. After $1.28 actual earnings per share reported by Alexion Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 0.00% EPS growth.
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. The company has market cap of $23.97 billion. The firm offers Soliris , a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. It has a 54.71 P/E ratio. It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia (HPP); and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency.
Investors sentiment decreased to 1.03 in 2017 Q4. Its down 0.14, from 1.17 in 2017Q3. It is negative, as 65 investors sold Alexion Pharmaceuticals, Inc. shares while 171 reduced holdings. 64 funds opened positions while 178 raised stakes. 204.38 million shares or 1.21% less from 206.89 million shares in 2017Q3 were reported. Amundi Pioneer Asset Mgmt Inc accumulated 1.45 million shares or 0.27% of the stock. Greenleaf Tru stated it has 0% of its portfolio in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). First Personal has invested 0% of its portfolio in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Fiera Cap reported 0% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Sit Inv stated it has 0.09% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Mitsubishi Ufj Securities Ltd accumulated 300 shares. Moreover, Rafferty Asset Mngmt has 0.03% invested in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) for 12,841 shares. Stifel Financial Corp reported 51,508 shares stake. 193,775 were reported by Chevy Chase. Profund Advsrs Ltd Limited Liability Company reported 96,797 shares stake. Lombard Odier Asset (Europe) accumulated 2,444 shares. Pennsylvania-based Philadelphia Tru has invested 0.03% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Bb&T Lc owns 3,391 shares. Seatown Holdg Pte Ltd holds 1.26% of its portfolio in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) for 111,000 shares. Exane Derivatives, France-based fund reported 419 shares.